RP Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

RP Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,846,154	Closed	-$28.8M	–	1
2025 Q1	$28.8M	Hold	3,846,154	–	–	20.78%	3
2024 Q4	$29.2M	Hold	3,846,154	–	–	12.84%	3
2024 Q3	$29.2M	Hold	3,846,154	–	–	12.84%	3
2024 Q2	$23.8M	Hold	3,846,154	–	–	13.29%	3
2024 Q1	$19.5M	Hold	3,846,154	–	–	10.85%	2
2023 Q4	$23M	Hold	3,846,154	–	–	15.49%	2
2023 Q3	$27.2M	Hold	3,846,154	–	–	26.28%	2
2023 Q2	$27.1M	Hold	3,846,154	–	–	27.82%	2
2023 Q1	$32.1M	Hold	3,846,154	–	–	44.43%	2
2022 Q4	$44.2M	Hold	3,846,154	–	–	52%	1
2022 Q3	$48.5M	Hold	3,846,154	–	–	22.39%	2
2022 Q2	$40.7M	Hold	3,846,154	–	–	16.07%	3
2022 Q1	$62.5M	Hold	3,846,154	–	–	25.44%	2
2021 Q4	$43M	Buy	+3,846,154	New	+$50.9M	18%	2

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RP Management's BCRX Position: Q2 2025 in Review

RP Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 3,846,154 shares — an estimated $28.8M sold.

RP Management first reported a position in BCRX in Q4 2021 and held it in 14 quarters. The position peaked at $62.5M in Q1 2022. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

RP Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
RP Management sold 3,846,154 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $28.8M.
RP Management first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 14 quarters.
RP Management's BioCryst Pharmaceuticals position peaked at $62.5M in Q1 2022.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on RP Management's 13F filing for Q2 2025.